Primary hepatic neuroendocrine tumor: Gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging
Acta Radiologica Short Reports · 2013
DOI: 10.1177/2047981613482897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Radiologica Short Reports, 2013. Verfasst von Soo-Heui Baek und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
We present a case of a 71-year-old man with prostate cancer who had no prior underlying liver disease. During metastatic evaluation, a solid mass in the liver was identified by computed tomography and ultrasound. Gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging demonstrated a well-defined, peripheral enhancing hepatic mass containing small cystic component. This lesion was diagnosed as hepatic neuroendocrine tumor. Primary neuroendocrine tumors of the liver are extremely rare. This case is interesting because of the rarity of this neoplasm and the unique radiologic findings despite its small size. Reviews of previously reported cases in the literature are also presented.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology.
Zitieren
APA
Baek, S. H., Yoon, J. H., & Kim, K. W. (2013). Primary hepatic neuroendocrine tumor: Gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging. Acta Radiologica Short Reports. https://doi.org/10.1177/2047981613482897
Vancouver
Baek SH, Yoon JH, Kim KW. Primary hepatic neuroendocrine tumor: Gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging. Acta Radiologica Short Reports. 2013. doi:10.1177/2047981613482897
BibTeX
@article{Baek2013,
author = {Baek, Soo-Heui and Yoon, Jung-Hee and Kim, Kwan-Woo},
title = {Primary hepatic neuroendocrine tumor: Gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging},
journal = {Acta Radiologica Short Reports},
year = {2013},
doi = {10.1177/2047981613482897}
}
EUVIMED